Dalton Pharma Services and Affectis Pharmaceuticals of Germany enter into a Contract Services Agreement
Affectis has contracted Dalton for the manufacturing of preclinical tox material with potential for cGMP production. Affectis is an exciting addition to Dalton's portfolio of world wide clients. Dalton has first hand experience advancing compounds from a range of therapeutic areas including Alzheimer's, cardiovascular diseases, HIV, anti-aging and now also affective disorders.
"With this agreement, Affectis reaches an important milestone of advancing its P2X7 agonist program into pre-clinical development" said Herbert Stadler, CEO of Affectis. "Dalton's manufacturing know-how will help Affectis bring a novel antidepressant candidate into the clinic."
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.